Clinical Trial Update: A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 1/2 study of raludotatug deruxtecan in recurrent ovarian cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Raludotatug Deruxtecan (raludotatug deruxtecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Ovarian Cancer Recurrent | Phase 1, Phase 2 | Status: RECRUITING